[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 10, 2013

Bone Marrow–Derived Cell Therapy After Myocardial Infarction

Lemuel A. Moyé, MD, PhD; Robert D. Simari, MD; Sonia I. Skarlatos, PhD; et al for the Cardiovascular Cell Therapy Research Network (CCTRN)
Author Affiliations

Author Affiliations: University of Texas School of Public Health, Houston (Dr Moyé; lemmoye@msn.com); Mayo Clinic, Rochester, Minnesota (Dr Simari); and National Heart, Lung, and Blood Institute, Bethesda, Maryland (Dr Skarlatos).

JAMA. 2013;309(14):1459-1460. doi:10.1001/jama.2013.2601

To the Editor: We would like to clarify several points in the Editorial1 accompanying the report of the Timing In Myocardial infarction Evaluation (TIME) trial.2

First, the automated system for extracting bone marrow–derived mononuclear cells (MNCs) used for the Cardiovascular Cell Therapy Research Network's (CCTRN’s) clinical trials uses Ficoll gradient centrifugation,3 which is similar to the manual method used more commonly.